SCHEMBL279637

SCHEMBL279637

Cc1ccc(C(=O)CN2CCSCC2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
HTT P42858 1/20 0.49
LMNA P02545 1/20 0.48
DAO P14920 1/20 0.44
NPC1 O15118 3/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.43
HTR1A P08908 1/20 0.43
POLB P06746 2/20 0.40
HPGD P15428 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
DUSP3 P51452 1/20 0.39
PTPN5 P54829 1/20 0.39
PTPN11 Q06124 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279616 0.86 RAB9A (0.49) ALDH1A1DAONPC1MAPTKDM4E
SCHEMBL279862 0.83 ALDH1A1 (0.51) ALDH1A1HTTLMNADAOMAPT
SCHEMBL279970 0.83 DAO (0.43) ALDH1A1HTTDAONPC1MAPT
SCHEMBL279617 0.82 DAO (0.42) ALDH1A1DAONPC1MAPTHTR1A
SCHEMBL279990 0.81 HTR1A (0.49) ALDH1A1HTTDAONPC1HTR1A
SCHEMBL279992 0.78 DAO (0.44) ALDH1A1LMNADAONPC1HTR1A
SCHEMBL279886 0.76 ALDH1A1 (0.42) ALDH1A1LMNADAONPC1HTR1A
SCHEMBL280132 0.75 SMN1; SMN2 (0.46) ALDH1A1LMNADAONPC1HTR1A
SCHEMBL280340 0.72 NPC1 (0.40) ALDH1A1LMNANPC1HTR1APOLB
SCHEMBL15979700 0.72 DAO (0.61) ALDH1A1LMNADAONPC1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL ALDH1A1 2047/4885HTT 1630/4885LMNA 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.